This study excluded uveal melanoma, but included all other subtypes provided they had progressed on previous therapy. With this broad population of patients with melanoma, those who received an ...

Our study results reveal a unique vulnerability in melanoma patients with neurofibromin 1 mutations, that an overexpression of the epidermal growth factor receptor pathway is essential for their ...

Recent reports show that experts have seen a rise in melanoma cases in Massachusetts, especially among younger women. NewsCenter 5 spoke to Dr. Jeff Yu, a dermatologist at Mass. General Hospital ...

Mitochondrial DNA emerges as a key factor in melanoma checkpoint inhibitor resistance, revealing new potential biomarker for patients.

Despite its success in advanced melanoma, Bristol Myers Squibb’s fixed-dose PD-1/LAG-3 combo, Opdualag, failed to move the needle in resected skin cancer. After revealing in February that ...

Years after it was removed, Katie Cooper's melanoma, which started as a small spot behind her ear, spread to her bones and spine. Now, facing a terminal diagnosis, she worries about missing her ...

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

Mom’s Melanoma Found in Unlikely Place: ‘Is This a Death Sentence?’ Michaela Peacock's hair stylist noticed that she had a mole on her scalp that had changed, prompting her to seek medical ...

Using multi-omics analysis, the team identified five adenosine phosphate signaling subtypes in melanoma, categorized into two major metaprograms: metabolic and inflammatory.

Boy, 15, with advanced melanoma recalls early symptom that doctors said was a sign of puberty Samuel Gee is spreading the importance of wearing sunscreen and not tanning after being diagnosed with ...

The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.

Circulating tumor cells (CTCs) are a reliable marker of disease progression in melanoma and can reliably be detected using flow cytometry, suggests a small study of patients with the skin disease ...